NNZ-2591
A synthetic analogue of cyclic glycine-proline investigated in neurodevelopmental disorders.
- Evidence grade
- CEarly Human Research
Early Human Research
- Regulatory status
- Clinical Trials
Investigational; no FDA-approved NNZ-2591 indication is established by the cited research.
- Human data
- Limited
Registered clinical trials exist
- Last reviewed
- October 27, 2026
Overview
A synthetic analogue of cyclic glycine-proline investigated in neurodevelopmental disorders.
Investigational; no FDA-approved NNZ-2591 indication is established by the cited research.
Open-label caregiver-rated changes may reflect expectation, natural variation or other care.
Why It's Being Studied
- Phelan-McDermid syndrome
- Neurodevelopmental research
Mechanism of Action
Its design relates to an IGF-1 metabolite, but the clinical mechanism and durable benefit remain under investigation.
Its design relates to an IGF-1 metabolite, but the clinical mechanism and durable benefit remain under investigation. Open-label caregiver-rated changes may reflect expectation, natural variation or other care.
From molecular target to clinical evidence
Tap each stage to see what happens.
Background: Clinical Peptide Medicines
Clinical peptide medicines include endocrine treatments, antimicrobial drugs, receptor blockers and targeted diagnostic or cancer agents. They do not share one mechanism or one set of indications.
An approval belongs to a specific medicine and indication. A diagnostic tracer, an antibiotic and a hormone are not interchangeable wellness products; read each profile's own mechanism and prescribing source.
Research Areas & Routes Studied
- Phelan-McDermid syndrome
- Neurodevelopmental research
- Oral clinical research
Evidence Summary
An open-label phase 2 Phelan-McDermid study included 18 participants; without a control group, symptom changes cannot establish efficacy.
Higher tiers carry more weight. Filled tiers have evidence for NNZ-2591; tap to read it.
- An open-label phase 2 Phelan-McDermid study included 18 participants; without a control group, symptom changes cannot establish efficacy.
1 cited sources.
- Phase 2 trial1
Human clinical evidence
- An open-label phase 2 Phelan-McDermid study included 18 participants; without a control group, symptom changes cannot establish efficacy.
Reported Adverse Events in Research
- Reported events included appetite and behavioral changes and somnolence; small samples cannot define uncommon risks.
Limitations of Current Evidence
- Open-label caregiver-rated changes may reflect expectation, natural variation or other care.
- Findings apply to the product, route and population studied; they do not establish benefits or safety for unrelated wellness uses or research-vial products.
How to Read This Research
- Is this a single molecule or a family of medicines?
- Is the use diagnostic, therapeutic or investigational?
- Does the quoted outcome match the exact product, formulation and population?
- Use the compound-specific mechanism above; this diagram describes drug development, not a shared biological pathway.
- Historical approval, present availability and off-label use are distinct questions.
- For radiopharmaceuticals and hospital medicines, specialist handling is part of the treatment context.
- Indication
- The condition and population for which a medicine is approved.
- Antagonist
- A compound that blocks activity at a receptor.
- Radiopharmaceutical
- A medicine containing a radioactive isotope for imaging or treatment.
Compare With Other Compounds
| NNZ-2591 | Trofinetide | |
|---|---|---|
| Evidence grade | C — Early Human Research | B — Moderate Human Evidence |
| Regulatory status | Clinical Trials | FDA Approved for Specific Indication |
| Human data | Limited | Yes |
| Clinical trials | Registered trials exist | Registered trials exist |
| Research routes | Oral clinical research | Oral approved medicine |
| Cited sources | 1 | 2 |
Frequently Asked Questions
Research References
- Phase 2 trial
NNZ-2591 — phase 2 trial